ResearchMoz

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

Transparency Market Research
Published Date » 2012-10-01
No. Of Pages » 162
   
 This report is an effort to identify factors, which will be the driving force behind the diabetes devices and drugs market and sub-markets in the nextfew years. Thereport provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the diabetes devices and drugs industry in terms of productand geography. We have used a combination of primary and secondary research to arrive at the market estimates, market shares and trends. We have adopted bottom up model to derive market size of the global diabetes devices and drugs market and further validated numbers with the key market participants and C-level executives.  
   
  This report highlights the industry with the...
TABLE OF CONTENTS

CHAPTER 1 PREFACE
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
1.3 METHODOLOGY
1.4 ASSUMPTIONS

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL DIABETES MARKET ANALYSIS
3.1 DIABETES: AGE-GROUP ANALYSIS
3.2 MARKET OVERVIEW
3.3 KEY MARKET TRENDS
3.4 GLOBAL DIABETES MARKET SIZE AND FORECAST, 2010 – 2018
3.4.1 TYPE I DIABETES MARKET SIZE AND FORECAST
3.4.2 TYPE II DIABETES MARKET SIZE AND FORECAST
3.4.3 DIABETES DEVICES MARKET SIZE AND FORECAST
3.4.4 DIABETES DRUGS MARKET SIZE AND FORECAST
3.5 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
3.6 MARKET DYNAMICS
3.6.1 DRIVERS
3.6.1.1 Growing Diabetic Population around the Globe
3.6.1.2 Changing Lifestyle and Obesity as a Leading Cause of Diabetes
3.6.1.3 Launch of New Generation Innovative Drugs Likely to Attract Consumers
3.6.2 RESTRAINTS
3.6.2.1 Lack of Awareness about Diabetes Diagnostics and Treatment
3.6.2.2 Adverse side-effects of drugs and the resulting litigation issues
3.6.3 OPPORTUNITIES
3.6.3.1 Increasing Awareness may Unleash the Untapped Market
3.7 IMPACT OF REGULATIONS ON TYPE II DIABETES MARKET GROWTH
3.7.1 RISE IN THE NUMBER OF BACKLOG OF DRUGS UNDER FDA REVIEW AND THE SHIFTING TIMELINES FOR THE SAME IN THE UNITEDSTATES
3.7.2 REGULATORS’ LAY MORE EMPHASIS ON ADEQUATE SAFETY DATA INSTEAD OF RELYING ONLY ON EFFICACY DATA FOR DRUG APPROVAL AND NEW DIRECTIVES FOR PATIENT SCREENING IN THE UNITED STATES
3.7.3 PROMOTION OF LOW-COST GENERICS TO LIMIT HEALTHCARE COSTS, HEALTHCARE INSURERS’ AND REGULATORS’
3.7.4 IN EMERGING MARKETS SUCH AS ASIA, PRICING CONTROLS ARE LIKELY TO BE PUT IN PLACE
3.8 FACTORS AFFECTING GLOBAL DIABETES DEVICES AND DRUGS MARKET
3.8.1 RISING INCIDENCE OF DIABETES IN KEY MARKETS SUCH AS U.S., U.K. AND GERMANY
3.8.2 RISING EDUCATION IS EXPECTED TO DECREASE DIABETES PREVALENCE BY 1.2%
3.8.3 PEOPLE WITH A DIABETES PARENT LEADS TO AN INCREASE OF 1.4%
3.8.4 SOCIAL FACTORS AFFECTING DIABETE
3.9 PORTERS FIVE FORECES ANALYSIS OF DIABETES DEVICES AND DRUGS MARKET 
3.9.1 BUYERS’ POWER
3.9.2 SUPPLIERS’ POWER
3.9.3 EXISTING RIVALRY
3.9.4 THREAT OF NEW ENTRANTS
3.9.5 THREAT OF SUBSTITUTE 
3.10 GLOBAL DIABETES DRUGS AND DEVICES REGULATORY SCENARIO

CHAPTER 4 GLOBAL DIABETES DEVICES AND DRUGS MARKET
4.1 GLOBAL DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2010 – 2018
4.1.1 BLOOD GLUCOSE MONITORING DEVICES, MARKET SIZE AND FORECAST
4.1.1.1 Lancets
4.1.1.2 Blood Sampling Devices
4.1.1.3 Blood Glucose Monitors
4.1.1.3.1 Drivers
4.1.1.3.1.1 Increasing awareness and simpler devices
4.1.1.3.1.2 Increase in disposable income
4.1.1.3.1.3 Declining prices
4.1.1.3.1.4 Improving compatibility
4.1.1.3.2 Restraints
4.1.1.3.2.1 Increase in competition leading to low prices
4.1.1.3.2.2 Private label brands
4.1.1.3.2.3 Awareness among patients is still a challenge
4.1.1.3.3 Key trends
4.1.1.4 New Development in Glucose Testing
4.1.2 OTHER TESTING DEVICES MARKET SIZE AND FORECAST
4.1.2.1 Hemoglobin A1c
4.1.2.1.1 Hemoglobin A1c Meters
4.1.2.1.2 Hemoglobin A1c Kits
4.1.2.2 Others
4.1.3 SOFTWARE PROGRAMS FOR DIABETES MONITORING, MARKET SIZE AND FORECAST
4.1.3.1 Web Software Programs for Diabetes Monitoring
4.1.3.2 Commercial Software
4.1.4 ARTIFICIAL PANCREAS, MARKET SIZE AND FORECAST
4.2 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2011 – 2018
4.2.1 DRIVERS
4.2.1.1 Improved Delivery Devices
4.2.1.2 Increased Risk with Oral Anti-Diabetes Drugs
4.2.1.3 Technological Advancement
4.2.2 RESTRAINTS
4.2.2.1 Associated Pain
4.2.2.2 Market boom for New Generation diabetic drugs
4.2.2.3 Cost Issues
4.2.3 OPPORTUNITIES
4.2.3.1 Novel insulin delivery method
4.2.4 GLOBAL ORAL DIABETES DRUG MARKET
4.2.4.1 Popular Anti-Diabetic Drugs World wide
4.2.4.2 Drivers
4.2.4.2.1 Novel drugs driving the market growth
4.2.4.2.2 Patent expiry of popular drugs
4.2.4.2.3 Painless Option
4.2.5 RESTRAINTS
4.2.5.1 Associated high risks
4.2.5.2 Improving options of insulin delivery devices
4.2.5.3 Trend of diabetic diet
4.2.6 OPPORTUNITIES
4.2.6.1 Diabetes Vaccines
4.2.6.2 Leveraging the patent expiry of popular drugs
4.2.7 INSULIN, MAKET SIZE AND FORECAST 
4.2.7.1 Market Size and Forecast
4.2.7.2 Global Insulin Market Share of Major Players, 2011 
4.2.7 2.1 Global Human Insulin Market Share of Major Players, 2011 
4.2.7 2.2 Global Modern Insulin Market Share of Major Players, 2011
4.2.7.3 Insulin Market Size and Forecast, By Action
4.2.7.3.1 Short Acting
4.2.7.3.2 Pre-Mixes
4.2.7.3.3 Long Acting
4.2.7.4 Insulin Market Size and Forecast, by Type
4.2.7.4.1 Human Insulin
4.2.7.4.2 Modern Insulin
4.2.7.4.3 Animal Insulin
4.2.7.5 Insulin Market Size and Forecast, by Purchase Type
4.2.7.5.1 Dosage
4.2.7.5.2 Bulk
4.2.8 INSULIN, DELIVERY MAKET SIZE AND FORECAST
4.2.8.1 Insulin Syringes Maket Size and Forecast 
4.2.8.2 Insulin Pens Maket Size and Forecast
4.2.8.3 Insulin Injectors Maket Size and Forecast 
4.2.8.4 Inhaled Insulin Maket Size and Forecast 
4.2.8.5 Insulin Pumps Maket Size and Forecast 
4.2.8.5.1 Drivers
4.2.8.5.1.1 Growing Diabetic Population
4.2.8.5.1.2 Advancement in Technology
4.2.9 ORAL HYPOGLYCEMIC AGENTS, MAKET SIZE AND FORECAST
4.2.9.1 KATP Blocker Maket Size and Forecast
4.2.9.2 Biguanides Maket Size and Forecast 
4.2.9.3 Alpha-Glucosidase Inhibitor Maket Size and Forecast 
4.2.9.4 Thiazolinediones/ Glitazones Maket Size and Forecast 
4.2.9.5 Incretin Mimetics/ GLP-1 Analogs Maket Size and Forecast 
4.2.9.6 DPP-4 InhibitorMaket Size and Forecast 
4.2.9.7 Amylin Mimetic Maket Size and Forecast 
4.2.9.8 SGLT2 Inhibitors Maket Size and Forecast 
4.2.9.9 Other Oral Hypoglycemic Agents Maket Size and Forecast 
4.2.10 CELL THERAPIES MAKET SIZE AND FORECAST

CHAPTER 5 GEOGRAPHY ANALYSIS
5.1 GLOBAL OVERVIEW
5.2 EUROPE DIABETES DEVICES AND DRUGS MARKET
5.2.1 INNOVATION DRIVING THE EUROPEAN MARKET
5.2.1.1 Undiagnosed patients high in European countries
5.2.1.2 Increasing R&D costs
5.2.2 RESTRAINTS
5.2.2.1 Case1
5.2.2.2 Case 2
5.2.2.3 Case 3
5.2.3 OPPORTUNITIES
5.2.3.1 Undiagnosed Diabetic Patient Population in Europe
5.2.4 EUROPE DIABETES MARKET SHARE OF MAJOR PLAYERS
5.2.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.2.5.1 Blood glucose monitoring devices, maket size and forecast
5.2.5.2 Other dibetes testing devices, maket size and forecast
5.2.5.3 Software programs for diabetes monitoring, maket size and forecast
5.2.5.4 Artificial pancreas, maket size and forecast
5.2.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.2.6.1 Insulin, maket size and forecast
5.2.6.2 Insulin delivery, maket size and forecast
5.2.6.3 Oral hypoglycemic agents, maket size and forecast
5.2.6.4 Cell therapies, maket size and forecast
5.3 ASIA PACIFIC DIABETES DEVICES AND DRUGS MARKET
5.3.1 CHINA
5.3.2 INDIA
5.3.3 SOUTH KOREA
5.3.4 TAIWAN
5.3.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.3.5.1 Blood glucose monitoring devices, maket size and forecast
5.3.5.2 Other dibetes testing devices, maket size and forecast
5.3.5.3 Software programs for diabetes monitoring, maket size and forecast
5.3.5.4 Artificial pancreas, maket size and forecast
5.3.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.3.6.1 Insulin, maket size and forecast
5.3.6.2 Insulin delivery, maket size and forecast
5.3.6.3 Oral hypoglycemic agents, maket size and forecast
5.3.6.4 Cell therapies, maket size and forecast
5.4 NORTH AMERICA DIABETES DEVICES AND DRUGS MARKET 
5.4.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST
5.4.1.1 Blood glucose monitoring devices, maket size and forecast
5.4.1.2 Other dibetes testing devices, maket size and forecast
5.4.1.3 Software programs for diabetes monitoring, maket size and forecast
5.4.1.4 Artificial pancreas, maket size and forecast  
5.4.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.4.2.1 Insulin, maket size and forecast
5.4.2.2 Insulin delivery, maket size and forecast
5.4.2.3 Oral hypoglycemic agents, maket size and forecast
5.4.2.4 Cell therapies, maket size and forecast
5.5 MIDDLE EAST AND AFRICA DIABETES DEVICES AND DRUGS MARKET 
5.5.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST  
5.5.1.1 Blood glucose monitoring devices, maket size and forecast
5.5.1.2 Other dibetes testing devices, maket size and forecast
5.5.1.3 Software programs for diabetes monitoring, maket size and forecast
5.5.1.4 Artificial pancreas, maket size and forecast 
5.5.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST 
5.5.2.1 Insulin, maket size and forecast
5.5.2.2 Insulin delivery, maket size and forecast
5.5.2.3 Oral hypoglycemic agents, maket size and forecast
5.5.2.4 Cell therapies, maket size and forecast 
5.6 LATIN AMERICDIABETES DEVICES AND DRUGS MARKET 
5.6.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.6.1.1 Blood glucose monitoring devices, maket size and forecast
5.6.1.2 Other dibetes testing devices, maket size and forecast
5.6.1.3 Software programs for diabetes monitoring, maket size and forecast
5.6.1.4 Artificial pancreas, maket size and forecast 
5.6.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST 
5.6.2.1 Insulin, maket size and forecast
5.6.2.2 Insulin delivery, maket size and forecast
5.6.2.3 Oral hypoglycemic agents, maket size and forecast
5.6.2.4 Cell therapies, maket size and forecast

CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 SUMMARY
6.2 MARKET SHARE OF MAJOR PLAYERS: GLOBAL DIABETES MARKET
6.3 GLOBAL DIABETES DEVICES MARKET SHARE OF MAJOR PLAYERS
6.4 GLOBAL DIABETES THERAPEUTIC MARKET SHARE OF MAJOR PLAYERS
6.4.1 INSULIN DELIVERY MARKET PLAYERS
6.4.2 GLOBAL DIABETES DRUGS MARKET SHARES OF MAJOR PLAYERS
6.5 CLINICAL TRIALS
6.6 RECENT DEVELOPMENTS
6.7 COMPETITIVE STRATEGY BY KEY PLAYERS

CHAPTER 7 COMPANY PROFILE
7.1 ABBOTT LABORATORIES
7.1.1 COMPANY OVERVIEW
7.1.2 REVENUE SHARE
7.1.3 RECENT DEALS
7.2 BRISTOL-MYERS SQUIBB (BMS)
7.2.1 COMPANY OVERVIEW
7.2.2 REVENUE SHARE
7.2.3 RECENT DEALS
7.3 DEXCOM
7.3.1 COMPANY OVERVIEW
7.3.2 REVENUE SHARE
7.3.3 RECENT DEALS
7.4 ELI LILLY
7.4.1 COMPANY OVERVIEW
7.4.2 REVENUE SHARE
7.4.3 RECENT DEALS
7.5 GLAXOSMITHKLINE
7.5.1 COMPANY OVERVIEW
7.5.2 REVENUE SHARE
7.5.3 RECENT DEALS
7.6 GLENMARK PHARMACEUTICALS
7.6.1 COMPANY OVERVIEW
7.6.2 REVENUE SHARE
7.6.3 RECENT DEALS
7.7 JOHNSON&JOHNSON
7.7.1 COMPANY OVERVIEW
7.7.2 REVENUE SHARE
7.7.3 RECENT DEALS
7.8 LUPIN
7.8.1 COMPANY OVERVIEW
7.8.2 REVENUE SHARE
7.8.3 RECENT DEALS
7.9 ROCHE
7.9.1 COMPANY OVERVIEW
7.9.2 REVENUE SHARE
7.9.3 RECENT DEALS
7.10 SANOFI
7.10.1 COMPANY OVERVIEW
7.10.2 REVENUE SHARE
7.10.3 RECENT DEALS

List of Tables

LIST OF TABLES

TABLE 1 OBESITY RATE IN THE U.S., BY STATE 2011 (%)
TABLE 2 CLINICAL TRIALS: US (ORAL ANTI-DIABETES DRUGS)
TABLE 3 CLINICAL TRIALS: CHINA (ORAL ANTI-DIABETES DRUGS)
TABLE 4 CLINICAL TRIALS: JAPAN (ORAL ANTI-DIABETES DRUGS)
TABLE 5 CLINICAL TRIALS: INDIA (ORAL ANTI-DIABETES DRUGS)
TABLE 6 CLINICAL TRIALS: UNITED KINGDOM (ORAL ANTI-DIABETIC DRUGS)
TABLE 7 CLINICAL TRIALS: GERMANY (ORAL ANTI-DIABETIC DRUGS)
TABLE 8 CLINICAL TRIALS: FRANCE (ORAL ANTI-DIABETIC DRUGS)
TABLE 9 CLINICAL TRIALS: US (ANTI-DIABETIC INJECTABLES)
TABLE 10 CLINICAL TRIALS: JAPAN (ANTI-DIABETIC INJECTABLES)
TABLE 11 CLINICAL TRIALS: CHINA (ANTI-DIABETIC INJECTABLES)
TABLE 12 CLINICAL TRIALS: INDIA (ANTI-DIABETIC INJECTABLES)
TABLE 13 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)
TABLE 14 CLINICAL TRIALS: UNITED KINGDOM (ANTI-DIABETIC INJECTABLES)
TABLE 15 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)
TABLE 16 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY GEOGRAPHY 2012 – 2018
TABLE 17 EUROPE DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 18 EUROPE  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2012 – 2018 (USD MILLION)
TABLE 19 EUROPE DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 20 ASIA PACIFIC DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 21 ASIA PACIFIC  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)
TABLE 22 ASIA PACIFIC THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 23 NORTH AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 24 NORTH AMERICA  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)
TABLE 25 NORTH AMERICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 29 LATIN AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 30 LATIN AMERICADIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 31 LATIN AMERICATHERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 32 CLINICAL TRIALS: UNITED STATES (INSULIN PUMPS)
TABLE 33 CLINICAL TRIALS: UNITED KINGDOM (INSULIN PUMPS)
TABLE 34 CLINICAL TRIALS: FRANCE (INSULIN PUMPS)
TABLE 35 CLINICAL TRIALS: GERMANY (INSULIN PUMPS)
TABLE 36 CLINICAL TRIALS: CHINA (INSULIN PUMPS)
TABLE 37 CLINICAL TRIALS: UNITED STATES (GLUCOSE MONITORS)
TABLE 38 CLINICAL TRIALS: UNITED KINGDOM (GLUCOSE MONITORS)
TABLE 39 CLINICAL TRIALS: FRANCE (GLUCOSE MONITORS)
TABLE 40 CLINICAL TRIALS: CHINA (GLUCOSE MONITORS)

List of Figures

LIST OF FIGURES

FIG. 1 GLOBAL PREVALENCE OF DIABETES AMONG VARIOUS AGE GROUPS
FIG. 2 GLOBAL DIABETES PREVELANCE, BY COUNTRY 2011
FIG. 3 DRUGS VS. DEVICES MARKET SHARE
FIG. 1 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 2 TYPE-I DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 3 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 4 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 5 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 6 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
FIG. 7 COUNTRY WISE DIABETES PATIENTS FORECAST, BY 2030 (MILLION)
FIG. 8 NUMBER OF DIABETES DRUGS IN DEVELOPMENT BY PHASE UNITED STATES, 2012
FIG. 9 NUMBER OF PEOPLE LEFT UNDIAGNOSED IN U.S., 2011 (MILLIONS)
FIG. 10 GLOBAL DIABETES DIAGNOSIS AND MONETORING MARKET SIZE AND FORECAST, BY CATEGORY 2010 - 2018 (USD MILLION)
FIG. 11 BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 12 LANCETS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 13 BLOOD SAMPLING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 14 MARKET SHARES (U.S. VS OTHERS)
FIG. 15 MARKET SHARE OF SMBG TESTING IN THE INVITRO- DIAGNOSTIC MARKET GLOBALLY
FIG. 16 BLOOD GLUCOSE METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 17 NEW DEVELOPMENTS IN GLUCOSE TESTING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 18 OTHER TESTING DEVICES BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 19 HEMOGLOBIN A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 20 HEMOGLOBIN A1C METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 21 HEMOGLOBIN A1C KITS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 22 OTHER A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 23 SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 24 WEB SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 25 COMMERCIAL SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 26 ARTIFICIAL PANCREAS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 27 MARKET SHARE
FIG. 28 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKETMARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 29 GLOBAL INSULINMARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 30 GLOBAL INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 31 GLOBAL MODERN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 32 GLOBAL HUMAN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 33 SHORT ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 34 PRE-MIXES INSULIN MARKET SIZE AND FORECAST, BY ACTION 2010 - 2018 (USD MILLION)
FIG. 35 LONG ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 36 HUMAN INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 37 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 38 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 39 INSULIN MARKET DOSAGE SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)
FIG. 40 INSULIN MARKET BULK SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)
FIG. 41 GLOBAL INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 42 INSULIN SYRINGES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 43 INSULIN PENS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 44 INSULIN INJECTORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 45 INHALED INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 46 INSULIN PUMPS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 47 KEY PARTICIPANTS: MARKET SHARES (2011)
FIG. 48 ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 49 KATP BLOCKER MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 50 BIGUANIDES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 51 ALPHA-GLUCOSIDASE INHIBITOR DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 52 THIAZOLINEDIONES/ GLITAZONES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 53 INCRETIN MIMETICS/ GLP-1 ANALOGS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 54 DPP-4 INHIBITORS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 55 AMYLIN MIMETIC DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 56 SGLT2 INHIBITORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 57 OTHER ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 58 CELL THERAPIES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 59 DIABETES PREVALENCE IN EUROPE
FIG. 60 POPULATION DISTRIBUTION WITH DIABETES (INITIATING DPP-IV, TZD,  GLP-1 OR INSULIN)
FIG. 61 UNDIAGNOSED DIABETIC POPULATION
FIG. 62 EUROPEAN DIABETES DRUGS MARKET SHARE (2012)
FIG. 63 DISTRIBUTION OF DIABETES DRUG MARKET IN EUROPE
FIG. 64 DIABETES PREVALENCE IN ASIAN COUNTRIES
FIG. 65 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 66 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 67 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 68 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 69 MARKET SHARE OF ABBOTT LABORATORIES
FIG. 70 REVENUE SHARES OF ABBOTT LABORATORIES
FIG. 71 REVENUE TRENDS OF DEXCOM
FIG. 72 REVENUE TRENDS OF ELI LILLY
FIG. 73 REVENUE CONTRIBUTIONOF ELI LILLY
FIG. 74 REVENUE TREND OF GLAXOSMITH
FIG. 75 REVENUE TREND OF GLAXOSMITH
FIG. 76 REVENUE TREND OF GLENMARK PHARMACEUTICALS
FIG. 77 REVENUECONTRIBUTION OF JOHNSON&JOHNSON
FIG. 78 REVENUE TREND OF JOHNSON&JOHNSON
FIG. 79 REVENUE TREND OF LUPIN
FIG. 80 REVENUE TREND OF ROCHE
FIG. 81 REVENUE CONTRIBUTION OF SANOFI
FIG. 82 REVENUE TREND OF SANOFI

Upcoming Reports:

Greece: rodenticides market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the rodenticides market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the rodenticides market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Greece: maize market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the maize market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the maize market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Palm Methyl Ester Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Palm methyl ester is a base used for producing biodiesel. It is produced from palm oil in a chemical process is known as transesterification. Methanol acts as a catalyst to convert palm oil to methyl ester. Palm oil cannot be directly used as engine oil due to higher viscosity than that of petroleum products. It is first converted to smaller molecules of methyl ester before being used  as a diesel fuel. Palm methyl ester is a ready substitute for diesel. It is successfully tested and used as fuel for power stations and passenger cars. Increasing use of this substitute...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

LG, Samsung to showcase home tech at IFA
Sep 2, 2014  
With this year’s IFA tech fair just round the corner, the participating companies are gearing up to showcase their latest gadgets. LG Electronics will be putting up an all-new set of appliances on display at the Internationale Funkausstellung (IFA) to be held from September 5 at Berlin. Televisions and wireless vacuum cleaners are two of its top devices on exhibit. LG’s...
Wine Consumption Prevents Cardiovascular Disease Only Among those who Exercise: Study
Sep 2, 2014  
Results from a latest study indicate that wine only prevents cardiovascular disease in people who engage in regular physical exercise. The study – In Vino Veritas – was presented by Prof. Milos Taborsky at the ESC Congress.  Prof. Taborsky, from the Czech Republic, said that this was the initial randomized trial that weighs both red and white wine against markers of...
New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...